South San Francisco startup Neurona Therapeutics raised a $23.5 million A round to support its work on a cell therapy approach to neurological disease. The round, led by the Column Group, will bankroll Neurona's efforts to develop cell-based treatments that can repair damaged neural circuits by implanting particular types of neurons. The nascent company was founded by neuroscientists and stem cell researchers from the University of California, San Francisco and Column partner Tim Kutzkey has stepped in to lead as CEO. Release